Analysis of NKAPL and PTPN22 risk allele disease associations in rheumatoid arthritis patient subgroups
| RAF | ||||||||
|---|---|---|---|---|---|---|---|---|
| SNP | Type | Cases | Controls | Risk allele | Case | Control | p Value* | OR (95% CI) |
| rs35656932 | SE− | 510 | 1901 | T | 0.150 | 0.077 | 1.20×10−12 | 2.1 (1.7 to 2.6) |
| SE+ | 1376 | 1901 | 0.105 | 0.077 | 4.70×10−5 | 1.4 (1.2 to 1.7) | ||
| Anti-CCP− | 402 | 1901 | 0.128 | 0.077 | 1.70×10−6 | 1.8 (1.4 to 2.3) | ||
| Anti-CCP+ | 913 | 1901 | 0.112 | 0.077 | 3.00×10−6 | 1.6 (1.3 to 1.9) | ||
| rs13208096 | SE− | 510 | 1901 | G | 0.145 | 0.076 | 3.50×10−11 | 2.1 (1.7 to 2.6) |
| SE+ | 1376 | 1901 | 0.105 | 0.076 | 8.10×10−5 | 1.4 (1.2 to 1.7) | ||
| Anti-CCP− | 402 | 1901 | 0.128 | 0.076 | 3.70×10−6 | 1.8 (1.4 to 2.3) | ||
| Anti-CCP+ | 913 | 1901 | 0.112 | 0.076 | 1.80×10−5 | 1.5 (1.3 to 1.9) | ||
| rs2476601 | SE− | 510 | 1901 | A | 0.126 | 0.093 | 2.40×10−3 | 1.4 (1.1 to 1.7) |
| (PTPN22) | SE+ | 1376 | 1901 | 0.162 | 0.093 | 1.40×10−16 | 1.9 (1.6 to 2.2) | |
| Anti-CCP− | 402 | 1901 | 0.116 | 0.093 | 5.10×10−2 | 1.3 (1.0 to 1.6) | ||
| Anti-CCP+ | 913 | 1901 | 0.155 | 0.093 | 1.50×10−11 | 1.8 (1.5 to 2.1) | ||
Data for subphenotype analyses were available for 1886 Canadian cases.
*Versus healthy controls.
CCP, cyclic citrullinated peptide; NKAPL, NF-κB activating protein-like; RAF: risk allele frequency; SE, presence of shared epitope encoding DRB1*0101, *0102,*0401,*0404,*0405,*0408, *0409, *1001 or *1402 alleles.